
|Articles|October 28, 2014
- Gastrointestinal Cancers (Issue 3)
- Volume 3
- Issue 1
Unanswered Questions Regarding the Treatment of Pancreatic NETs
Author(s)James C. Yao, MD
James C. Yao, MD, gives an overview of the questions that still remain regarding the treatment of pancreatic neuroendocrine tumors (NETs).
Advertisement
James C. Yao, MD, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, gives an overview of the questions that still remain regarding the treatment of pancreatic neuroendocrine tumors (NETs).
Read more about the treatment of pancreatic NETs > >
Articles in this issue
over 11 years ago
Targeted Agents and Combinations Being Studied in Pancreatic NETsover 11 years ago
Sequencing Agents for the Treatment of Pancreatic NETsover 11 years ago
Research on Epidemiology of GIST Identifies Risk Factorsover 11 years ago
Antiangiogenic Strategies for mCRC Need Further Explorationover 11 years ago
Coping With Comorbidities in Hepatocellular Cancerover 11 years ago
Strategies in Surveillance: Hepatocellular Carcinomaover 11 years ago
Immunotherapy and Viral Therapy for Pancreatic CancerAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















